Quarterly report pursuant to Section 13 or 15(d)

Nature of Business and Summary of Significant Accounting Policies - Additional Information (Details)

v3.22.2.2
Nature of Business and Summary of Significant Accounting Policies - Additional Information (Details)
 1 Months Ended 2 Months Ended 6 Months Ended
Aug. 03, 2022
USD ($)
$ / shares
shares
Aug. 01, 2022
USD ($)
$ / shares
shares
May 31, 2022
USD ($)
$ / shares
shares
Feb. 28, 2022
USD ($)
$ / shares
shares
Jun. 30, 2022
USD ($)
shares
Jun. 30, 2021
shares
Dec. 31, 2021
USD ($)
Aug. 12, 2021
Jul. 31, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
State of incorporation         DE        
Date of incorporation         Aug. 03, 2018        
Common stock, conversion description         minority stockholder of THIO received one share of MAIA common stock for each share of THIO common stock owned prior to the merger.        
Common stock, conversion ratio         1        
Working capital         $ 5,512,072        
Accumulated deficit         (35,157,721)   $ (28,437,993)    
Cash         8,150,012   10,574,292    
Current liabilities         3,097,566        
Revenues         0        
Number of common stock sold | shares     11,111 263,729          
Sale of common stock, price per share | $ / shares     $ 9 $ 9          
Gross proceeds from sale of common stock     $ 99,999 $ 2,373,561 2,473,561        
Cash equivalents         $ 0   $ 0    
Number of warrants issued | shares         0        
Accounting Standards Update [Extensible Enumeration]         us-gaap:AccountingStandardsUpdate201602Member        
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]         true        
Change in Accounting Principle, Accounting Standards Update, Adoption Date         Jan. 01, 2022        
Subsequent Event                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Gross proceeds from sale of common stock $ 9,200,000                
IPO | Subsequent Event                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Number of common stock sold | shares   2,000,000              
Sale of common stock, price per share | $ / shares   $ 5              
Gross proceeds from initial public offering   $ 10,000,000              
Overallotment option | Subsequent Event                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Number of common stock sold | shares 300,000                
Sale of common stock, price per share | $ / shares $ 5                
Gross proceeds from initial public offering $ 1,500,000                
MAIA Biotechnology, Inc. | THIO Therapeutics, Inc.                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Ownership percentage by parent               93.30%  
Minority stockholder ownership percentage               6.70%  
MAIA Biotechnology, Inc. | MAIA Drug Development Corporation                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Ownership percentage by parent                 100.00%
DGD Pharmaceuticals Corporation                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
State of incorporation         DE        
Date of incorporation         Apr. 01, 2019        
MAIA Drug Development Corporation                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
State of incorporation         TX        
Date of incorporation         Sep. 10, 2018        
DGD or THIO                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Number of common stock sold | shares           0